Efficacy of iguratimod in the treatment of patients with palindromic rheumatism ineffective to methotrexate or hydroxychloroquine

Mengjie Chen, Yongjun Cheng, Guang Jin, Yue Tu, Qi Zhang, Chuanfu Zhang, Wenlong WangFrontiers in Immunology 2025 · DOI

TL;DR

This study investigates the effectiveness of iguratimod (IGU) in treating palindromic rheumatism (PR) in patients who haven't responded well to standard treatments like methotrexate (MTX) and hydroxychloroquine (HCQ). The findings suggest IGU is a promising option, significantly reducing disease attacks and improving remission duration with a good safety profile.

What Problem Does This Paper Address?

Palindromic rheumatism (PR) is a rare inflammatory arthritis characterized by recurrent, self-limiting joint inflammation. Despite its similarities to rheumatoid arthritis (RA), PR has a complex pathogenesis and lacks established treatment guidelines. Current treatments, primarily MTX and HCQ, are not effective for all patients, leading to a need for alternative therapies. This paper addresses the gap in understanding the efficacy and safety of iguratimod (IGU), a novel synthetic disease-modifying antirheumatic drug (DMARD), for PR patients who are refractory to existing treatments.

Methods

This was a retrospective study conducted at the First People's Hospital of Wenling. The researchers analyzed data from 32 patients diagnosed with PR who had previously shown a poor response to MTX and/or HCQ. These patients were then switched to either IGU monotherapy (25 mg twice daily) or a combination of IGU (25 mg twice daily) and MTX (10 mg weekly). The primary outcomes measured were the frequency and duration of disease attacks over a three-month period. Remission was defined as complete (no attacks for three months), partial (at least 50% reduction in attack frequency), or no remission (less than 50% reduction). Statistical analyses included paired t-tests, Wilcoxon matched-pairs signed rank tests, and Kaplan-Meier curves to compare outcomes before and after IGU treatment and between treatment groups.

Datasets

Not discussed in the paper. The study utilized retrospective clinical data collected from electronic medical records and telephone follow-ups of patients treated at a single institution.

Key Insights and Ideas

  • IGU as a viable alternative for refractory PR: The study provides evidence that IGU can be an effective treatment option for patients with PR who have not benefited from MTX or HCQ, addressing a significant unmet need.
  • Dual mechanism potential: The authors hypothesize that IGU's dual anti-inflammatory and immunomodulatory effects, targeting cytokines and immune cells, align well with the presumed mixed autoimmune and autoinflammatory nature of PR.
  • Potential for simplified treatment: The study found no significant difference in remission time between IGU monotherapy and IGU combined with MTX, suggesting that IGU might offer efficacy with a potentially simpler regimen, reducing the burden of polypharmacy.
  • Seronegative PR distinctiveness: The study focused on seronegative PR patients (negative for RF and anti-CCP antibodies), noting that this subgroup is less likely to progress to RA compared to seropositive patients, highlighting potential differences in pathogenesis and prognosis.

Key Results

  • Reduced attack frequency: Patients experienced a significant reduction in the number of attacks over a three-month period (1.3 ± 1.4 attacks after IGU vs. 5.8 ± 2.0 attacks before IGU, P < 0.0001).
  • Prolonged remission duration: The duration of remission significantly increased (78.0(33.8,99.0) days after IGU vs. 15.0(13.0,22.0) days before IGU, P < 0.0001).
  • Shorter attack duration: The length of each individual attack was also reduced (2.1 ± 0.7 days after IGU vs. 2.5 ± 0.8 days before IGU, P=0.0042).
  • Remission rates: After treatment with IGU, 43.75% of patients achieved complete remission, and another 43.75% achieved partial remission.
  • Safety profile: Only one patient discontinued IGU due to gastric upset, indicating a generally favorable safety profile.
  • No progression to RA: Importantly, no patient in the study progressed to rheumatoid arthritis during the follow-up period.

Limitations and Future Work

The authors acknowledge several limitations:

  • Small sample size: The rarity of PR and the specific inclusion criteria (refractory to MTX/HCQ) resulted in a small cohort (n=32).
  • Retrospective design: The study's retrospective nature means it lacks a control group and relies on existing data, which may not be standardized.
  • Lack of validated tools: No validated tools were used to assess disease activity and efficacy, relying on attack frequency and duration.
  • Focus on refractory PR: The findings are specific to patients who failed prior treatments, and generalizability to all PR patients may be limited.
  • Potential bias: The study did not adjust for prior DMARD exposure or baseline attack frequency in its evaluation.

Future work suggested includes:

  • Larger, prospective studies: Real-world studies or randomized controlled trials (RCTs) with larger samples are needed to confirm the efficacy and safety of IGU.
  • Formal diagnostic and response criteria: Development of standardized criteria for PR diagnosis and treatment response is crucial.
  • Stratified management: Investigating the efficacy of IGU in patients with different disease states.
  • Exploration of biomarkers: Further research into inflammatory biomarkers (e.g., IL-6, MCP-1).
  • Long-term PR to RA progression tracking: Monitoring the progression of PR patients to RA.

Summary updated

Abstract

Iguratimod has demonstrated favorable efficacy and safety in the treatment of patients with PR who have not responded adequately to MTX and HCQ, which needs to be further confirmed.
BibTeX
@inproceedings{chen2025efficacy,
  author = {Mengjie Chen and Yongjun Cheng and Guang Jin and Yue Tu and Qi Zhang and Chuanfu Zhang and Wenlong Wang},
  title = {{Efficacy of iguratimod in the treatment of patients with palindromic rheumatism ineffective to methotrexate or hydroxychloroquine}},
  booktitle = {Frontiers in Immunology},
  year = {2025},
  doi = {10.3389/fimmu.2025.1613129},
}
Figure